Summary & Overview
HCPCS Level II Q4265: Neostim per Square Centimeter, Add-On
HCPCS Level II code Q4265 denotes neostimulation therapy billed per square centimeter as an add-on to a primary procedure. The code is used when topical or localized neostimulation is applied and charged in addition to the main service, reflecting granular, area-based dosing or treatment coverage. Nationally, add-on codes like Q4265 matter because they affect how adjunct therapies are reported and reimbursed across outpatient and ambulatory procedure settings, and they can influence bundled payment calculations and claims adjudication.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn the clinical context for when an add-on, area-based neostimulation service would be reported, typical sites of service where it appears, and the implications for billing workflow. The publication also summarizes common modifiers in use, typical payer considerations, and where to find additional code-specific guidance.
This briefing provides national-level information: a clear definition of the code and service type, the expected clinical scenarios for add-on neostimulation, a summary of payer coverage landscape, and notes on documentation elements that commonly accompany area-based adjunct therapies. Data not available in the input are identified where applicable.
Billing Code Overview
HCPCS Level II code Q4265 describes Neostim tl, per square centimeter (add-on, list separately in addition to primary procedure). This code represents an add-on billing entry for application of a neostimulation topical/locally delivered therapy quantified by treated surface area in square centimeters.
-
Service type: Topical or local neostimulation therapy applied per square centimeter as an adjunct to a primary procedure
-
Typical site of service: Ambulatory procedure settings or outpatient clinics where the primary procedure is performed
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A patient with chronic wound-related pain or impaired wound healing after surgical debridement presents to an outpatient wound care clinic or hospital inpatient service. The clinician applies a topical neurostimulation agent, billed as Q4265 (Neostim tl, per square centimeter), as an add-on to a primary wound care procedure such as debridement, negative-pressure wound therapy dressing change, or complex dressing application. Typical workflow: wound assessment and measurement; documentation of wound size in square centimeters; preparation of wound bed; application of the neostimulation topical agent to the measured wound surface; photographing and documenting the area treated and quantity applied (area × unit dosing); billing Q4265 as an add-on code in conjunction with the primary procedure code for the debridement or other wound intervention; application of appropriate modifiers based on circumstance (e.g., anesthesia, increased procedural services, discontinued procedure, assistant surgeon). Typical sites of service include outpatient wound care clinics, ambulatory surgery centers, emergency departments, and inpatient acute care units. Typical patient scenarios include diabetic foot ulcers, venous stasis ulcers, pressure injuries, or post-surgical wounds with delayed healing where topical neurostimulation is used to promote local neuromodulation and analgesia as an adjunct to primary wound therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|